Clinical Trial Update: A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers [Phase 2]

View source ↗

Summary

Phase 2 study of Fosbretabulin in pancreatic or gastrointestinal neuroendocrine tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Fosbretabulin (fosbretabulin)

Snippet

Sponsor: Mateon Therapeutics | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED | Results posted: 2017-10-19